In this year-end episode for 2024, Alison Savas invites Antipodes’ Sector Portfolio Managers to discuss their outlook for 2025. Each PM shares their insights on key sectors and stocks to watch in the new year, including a stock they believe will outperform and one they advise investors to steer clear of.
Key Times:
0:35 | Graham Hay – Hardware, Industrials & Commodities Portfolio Manager
- Stock to watch: Keysight Technologies, Inc. (NYSE: KEYS)
- Sector to avoid: Large cap technology stocks
8:45 | Nick Cameron – Healthcare Portfolio Manager
- Stock to watch: Alcon AG (SWX: ALC)
- Sector to avoid: Small to mid-cap medical device companies
16:15 | Max Shramchenko – Infrastructure Portfolio Manager
- Stock to watch: RWE AG (ETR: RWE)
- Sector to watch: Conventional power generating assets in US
23:15 | James Rodda – Developed Markets, Technology, Media and Telecommunications Portfolio Manager
- Stock to watch: Alphabet Inc (NASDAQ: GOOG)
- Sector to watch: Large cap technology stocks (ex Alphabet)
28:30 | John Stavliotis – Emerging Markets Portfolio Manager
- Stock to watch: DiDi Global Inc. (ADR: DIDIY)
- Sector to watch: Indian Mid cap Universe
More about Antipodes Partners: https://antipodes.com/
Stock commentary is illustrative only, not a recommendation to buy, hold, or sell any security.
You can subscribe to our podcast on Apple, Google or Spotify, to be notified as soon as upcomingepisodes are published
Subscribe to receive the latest news and insights from the Antipodes team
IMPORTANT INFORMATION:
All content in respect of the Antipodes Global Shares (Quoted Managed Fund) (ARSN 625 560 269), the Antipodes Global Fund – Long (ARSN 118 075 764), the Antipodes Global Fund (ARSN 087 719 515), and the Antipodes Emerging Markets (Managed Fund) (ARSN 096 451 393) is issued by Pinnacle Fund Services Limited ABN 29 082 494 371 AFSL 238 371 (“PFSL”) as responsible entity of the Funds and is prepared by Antipodes Partners Limited (ABN 29 602 042 035) (AFSL 481580) (“Antipodes”) as the investment manager of the Trust. PFSL is not licensed to provide financial product advice.
The information provided is of a general nature only and has been prepared without taking into account your objectives, financial situation or needs. Before making an investment decision in respect of the Funds, you should consider the current Product Disclosure Statement (‘PDS’) and Target Market Determination (‘TMD’) of the Funds and the Fund’s other periodic and continuous disclosure announcements lodged with the ASX, which are available at www.asx.com.au, and assess whether the Fund is appropriate given your objectives, financial situation or needs. If you require advice that takes into account your personal circumstances, you should consult a licensed or authorised financial adviser. The Product Disclosure Statement (‘PDS’) and Target Market Determination (‘TMD’) of the relevant Fund are available via below links. Any potential investor should consider the PDS and TMD before deciding whether to acquire, or continue to hold units in, the Fund.
Links to Product Disclosure Statement: IOF0045AU, WHT0057AU, IOF0203AU, WHT3997AU
Links to Target Market Determination: IOF0045AU, WHT0057AU, IOF0203AU, WHT3997AU
For historic TMD’s please contact Pinnacle client service Phone 1300 010 311 or Email service@pinnacleinvestment.com
Neither PFSL nor Antipodes guarantees repayment of capital or any particular rate of return from the Funds. Neither PFSL nor Antipodes gives any representation or warranty as to the currency, reliability, completeness or accuracy of the information contained in this content. All opinions and estimates included in this website constitute judgments of Antipodes as at the date of website creation and are subject to change without notice. Past performance is not a reliable indicator of future performance.